研究单位：[1]BeiGene[2]Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan, Hubei, China, 430030[3]Xiangya Hospital central South University Changsha, Hunan, China, 410008[4]Hunan Cancer Hospital Changsha, Hunan, China, 410013[5]Jiangsu Cancer Hospital Nanjing, Jiangsu, China, 210000[6]The First Affiliated Hospital of Nanchang University Nanchang, Jiangxi, China, 330006[7]Jiangxi Cancer Hospital Nanchang, Jiangxi, China, 330029[8]The First Affiliated Hospital of Dalian Medical University Dalian, Liaoning, China, 116027[9]The Second Hospital of Dalian Medical University Dalian, Liaoning, China, 116027[10]The First Hospital of China Medical University Shenyang, Liaoning, China, 110001[11]Liaoning Cancer Hospital Shenyang, Liaoning, China, 110042[12]Fudan University Shanghai Cancer Center Shanghai, Shanghai, China, 200032[13]Fudan University Zhongshan Hospital Shanghai, Shanghai, China, 200032[14]Fudan University Hua Dong Hospital Shanghai, Shanghai, China, 200040[15]The Second Affiliated Hospital of Xi'an Jiaotong University Xi'an, Shanxi, China, 710004[16]West China Hospital, Sichuan University Chengdu, Sichuan, China, 610041[17]The Second Hospital of Tianjin Medical University Tianjin, Tianjin, China, 300211[18]Zhejiang Provincial People's Hospital Hangzhou, Zhejiang, China, 310014[19]Samsung Medical Center Seoul, Soul, Korea, Republic of, 100021[20]Severance Hospital Seoul, Korea, Republic of[21]Cancer Hospital Chinese Academy of Medical Sciences Beijing, Beijing, China, 100021[22]Peking University First Hospital Beijing, Beijing, China, 100034[23]Fujian Medical University Union Hospital Fuzhou, Fujian, China, 350001[24]Sun Yat-Sen Memorial Hospital,Sun Yat-Sen University Guangzhou, Guangdong, China, 510120
研究目的：
This is a single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of the anti- programmed cell death-1(PD-1) monoclonal antibody BGB-A317 in participants with PD-L1+, locally advanced or metastatic Urothelial Bladder Cancer (UBC) who have progressed during or following a platinum-containing regimen
